Septic shock in the pediatric patient: Pathogenesis and novel treatments.
Burns
Jeffrey P
JP
Medical-Surgical Intensive Care Unit, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts, USA. Jeffrey.Burns@TCH.harvard.edu
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D023181:Antimicrobial Cationic Peptides; D000990:Antithrombin III / Q000009:adverse effects / Q000627:therapeutic use; D001798:Blood Proteins / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008565:Membrane Proteins; D015337:Multicenter Studies as Topic; D011486:Protein C / Q000627:therapeutic use; D018805:Sepsis / Q000150:complications* / Q000628:therapy; D012772:Shock, Septic / Q000209:etiology / Q000628:therapy; D018746:Systemic Inflammatory Response Syndrome / Q000209:etiology / Q000628:therapy; D019851:Thrombophilia / Q000209:etiology; D016896:Treatment Outcome
D023181:Antimicrobial Cationic Peptides; D001798:Blood Proteins; D008565:Membrane Proteins; D011486:Protein C; C021623:bactericidal permeability increasing protein; D000990:Antithrombin III; D006493:Heparin